- European clinical assessment of RLF-100(TM) for the treatment of COVID-19 induced lung injury planned to begin in Q1 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 18, 2020 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Syneos Health(R) (Nasdaq:SYNH), a leading global clinical research organization (CRO), to run the European clinical trial in severe COVID-19 induced lung injury, as well as future trials in other indications to be conducted in Europe. Relief has also selected AMRI, a global contract development and manufacturing organization (CDMO), who will provide aseptic fill/finish manufacturing of RLF-100TM at their Glasgow, UK, facility. European clinical assessment of RLF-100TM is slated to beginin Q1 2021.
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, commented: "We are pleased to bring on board highly experienced service partners that are critical to successfully advancing our clinical development activities in Europe. As a global therapeutically aligned organization, Syneos Health(R) brings forward deep respiratory therapeutic expertise and the ability to activate clinical trials across multiple countries. AMRI's Glasgow team is a renowned global provider of contract manufacturing services and will support our sterile fill/finish drug product manufacturing needs. We believe these collaborations position Relief to develop RLF-100(TM) as quickly as possible in Europe."
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100(TM) (aviptadil), synthetic vasoactive intestinal peptide (VIP), is being investigated, in cooperation with NeuroRx Inc., in two placebo-controlled U.S. Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. RLF-100(TM) is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100(TM) under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100(TM).
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.
RELIEF THERAPEUTICS Holding AG
Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
Mail: [email protected]
|FOR MEDIA/INVESTOR INQUIRIES:
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: [email protected]
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: Relief Therapeutics Holdings AG via EQS Newswire